Clinical Trials on Hemostatics in Czechia

Total 123 results

AGC Biologics S.p.A.
Horizon 2020 - European Commission

Terminated

Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Acute Myeloid Leukemia | Multiple Myeloma

Italy, Czechia
University Hospital, Motol

Completed

Primary Hemostasis Pathology in Patients on ECMO During Lung Transplantation

ECMO Primary Hemostasis Pathology

Czechia
Masaryk University
Brno University Hospital

Completed

Comparison of Viscoelastic Measurement by ROTEM® Delta and ClotPro® in Trauma Patients. (ROTCLOT)

Coagulation Disorder | Polytrauma

Czechia
Masaryk University
Brno University Hospital

Recruiting

Incidence of Trauma Induced Coagulopathy in Patients With Prehospital Administration of Fibrinogen (TICAF)

Hemorrhage | Trauma | Coagulopathy

Czechia
University Hospital, Motol

Completed

ROTEM Assessment of Modern Crystalloid, Hydroxyethyl Starch and Gelatin Effect on Coagulation

Coagulopathy

Czechia
University Hospital, Motol

Terminated

Point-of-care Management of Coagulopathy in Lung Transplantation

Lung Transplantation

Czechia
Zdravotnicka Zachranna Sluzba Kralovehradeckeho...
University Hospital Hradec Kralove

Unknown

Rapid Administration of Blood by HEMS in Trauma (RABBIT)

Wounds and Injuries | Trauma | Acute Coagulopathy

Czechia
Brno University Hospital

Recruiting

Effect of Prophylactic Fibrinogen Concentrate In Scoliosis Surgery (EFISS)

Bleeding | Spine Deformity | Coagulopathy, Consumption | Fibrinogen

Czechia
Oncopeptides AB

Withdrawn

A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma (COAST)

Multiple Myeloma | Relapse Multiple Myeloma

Czechia
European Myeloma Network
EMN Research Italy

Active, not recruiting

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Multiple Myeloma

Czechia, Greece, Italy
Hoffmann-La Roche

Completed

A Study of Mircera in Anemic Patients With Multiple Myeloma

Anemia

Poland, Czechia
Baxter Healthcare Corporation

Completed

Hemopatch Performance Evaluation: A Prospective Observational Registry

Air Leakage | Dura Mater Nick Cut or Tear | Hemostatis | Body Fluid Leakage

Germany, Spain, Czechia, Italy, Austria
Masaryk Hospital Krajská zdravotní a.s.

Completed

Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma

Coagulation Disorder | Multiple Trauma | Coagulation Defect; Acquired | Coagulation Factor Deficiency

Czechia
European Society of Anaesthesiology

Completed

European Transfusion Practice and Outcome Study (ETPOS)

Blood Coagulation Disorders | Anemia | Surgery | Erythrocyte Transfusion | Habits

Sweden, Israel, Spain, Czechia, Greece, Croatia, Estonia, Germany
European Myeloma Network
Sanofi; Amgen; EMN Research Italy

Active, not recruiting

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) (IsKia)

Multiple Myeloma

Czechia, Germany, Greece, Italy, Netherlands, Norway, Spain
Biotest
PRA Health Sciences

Completed

Adjusted Fibrinogen Replacement Strategy (AdFIrst)

Bleeding Disorder | Hypofibrinogenemia; Acquired

Belgium, Czechia, Germany, Poland, Spain, Switzerland, United Kingdom
Oncopeptides AB

Terminated

PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function (BRIDGE)

Multiple Myeloma | Renal Impairment

Greece, Czechia, Poland
Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed

Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

Czechia, Austria, Germany
Oncopeptides AB

Terminated

Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM (ANCHOR)

Multiple Myeloma

United States, France, Spain, Czechia
European Myeloma Network
Janssen Research & Development, LLC

Active, not recruiting

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma (Perseus)

Multiple Myeloma

Norway, Denmark, Netherlands, Czechia, Australia, Turkey, Spain, Belgium, Switzerland, France, Greece, Italy, Poland
Austrian Forum Against Cancer

Completed

Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma (BBD)

Multiple Myeloma

Austria, Czech Republic
Stichting European Myeloma Network
Fondazione EMN Italy Onlus

Completed

COVID-19 Infection and Multiple Myeloma (EMN-COVID)

Covid19 | Multiple Myeloma | Corona Virus Infection

Czechia, Netherlands, United Kingdom, Belgium, Germany, Austria, Greece, Italy
Pharmacyclics LLC.
Celgene Corporation

Terminated

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Czechia, Germany, Greece
Austrian Forum Against Cancer

Completed

Bortezomib-Dexamethasone-Doxorubicin-Study

Multiple Myeloma | Renal Insuficiency

Austria, Czech Republic
Millennium Pharmaceuticals, Inc.

Completed

Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United Kingdom, Spain, Canada, United States, Czechia
Bayer

Completed

Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment (BONA)

Breast Neoplasms | Prostatic Neoplasms | Multiple Myeloma | Osteolysis

Czech Republic
Hoffmann-La Roche

Completed

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Spain, Denmark, Netherlands, Sweden, Poland, France, Germany, Czechia, Norway
Sanofi

Terminated

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Plasma Cell Myeloma

Taiwan, United States, Czechia, France, Greece, Spain
Austrian Forum Against Cancer

Unknown

Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure

Multiple Myeloma Light Chain Induced Renal Insufficiency

Austria, Czech Republic
Gilead Sciences

Completed

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Czechia, Canada
Pharmacyclics Switzerland GmbH
Janssen Research & Development, LLC

Completed

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Spain, Germany, Turkey, Greece, Italy, Czechia
Sanofi

Active, not recruiting

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Australia, Czechia, Brazil, Japan, Greece, Portugal
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Multiple Myeloma

United Kingdom, Czechia, Australia, Austria, Belgium, Denmark, Germany, Greece, Italy, Netherlands, Norway, Serbia, Switzerland, Turkey, Brazil
Molecular Partners AG

Completed

A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma

Multiple Myeloma in Relapse

Poland, Italy, Germany, Denmark, Czechia, Austria
Oncopeptides AB

Terminated

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma (LIGHTHOUSE)

Relapsed Multiple Myeloma | Relapsed-Refractory Multiple Myeloma

Serbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
Sanofi

Recruiting

A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Relapsed/Refractory Multiple Myeloma | Amyloid Light-chain Amyloidosis

Italy, Australia, Hungary, United Kingdom, Czechia, Belgium, Spain
European Myeloma Network
Janssen Research & Development, LLC

Active, not recruiting

Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone (EMN14)

Multiple Myeloma

Netherlands, Belgium, Germany, Spain, Czechia, Greece, Italy, Denmark, Serbia, Turkey
Sanofi

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

Plasma Cell Myeloma

United States, Czechia, France
Stichting European Myeloma Network
Janssen, LP

Recruiting

European Myeloma Network (EMN) Sample Project (EMN36)

Multiple Myeloma | Smoldering Multiple Myeloma | Plasma Cell Leukemia | MGUS | Extramedullary Myeloma

Italy, Austria, Czechia, Greece, Serbia
Genentech, Inc.
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (CAMMA 1)

Multiple Myeloma

Korea, Republic of, United States, Denmark, Italy, Spain, France, Japan, Israel, United Kingdom, Poland, Australia, Canada, Czechia
Takeda

Recruiting

Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

Multiple Myeloma | Secondary Immunodeficiency (SID)

Greece, Spain, Italy, Romania, Argentina, Czechia, France, Germany, Poland, Sweden, Turkey
Pfizer

Completed

An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Multiple Myeloma

United States, Germany, Czech Republic
Sanofi

Recruiting

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Plasma Cell Myeloma

Czechia, Australia, Chile, France, Spain, United States, Brazil, China, Greece, Japan, Korea, Republic of, Sweden, Taiwan, Finland, Italy, Russian Federation
AEterna Zentaris
Dana-Farber Cancer Institute

Terminated

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Multiple Myeloma

Israel, Spain, Korea, Republic of, United States, Russian Federation, Canada, Ireland, Czechia, Slovakia
Novo Nordisk A/S

Terminated

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding (CONTROL)

Trauma | Acquired Bleeding Disorder

Spain, Hong Kong, Germany, France, United Kingdom, Brazil, Italy, Hungary, Netherlands, United States, Switzerland, Czech Republic, Greece, South Africa
Takeda

Completed

A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

United States, Netherlands, Czechia, France, Greece, Poland
Sanofi

Completed

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Plasma Cell Myeloma

France, Italy, Czechia, Greece, Spain, Canada, Australia, United States, Brazil, Hungary
Janssen-Cilag International NV

Completed

Velcade Consolidation Bone Study

Multiple Myeloma

Turkey, Greece, Czech Republic, Austria, Germany, Sweden, United Kingdom, Denmark
Celgene

Active, not recruiting

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Multiple Myeloma

United States, Canada, Italy, Czechia, Denmark, France, Germany, Greece, Spain
Janssen Research & Development, LLC

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

Multiple Myeloma

Belgium, Korea, Republic of, Australia, United Kingdom, France, Sweden, Spain, Turkey, Italy, Czechia, Netherlands, Poland, Switzerland, Germany

Clinical Trials on Hemostatics in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations